Maze Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 |
|---|---|---|---|
| Income Statement | |||
| Revenue | — | $167.5M | — |
| Research and development | $108.4M | $83.5M | — |
| Operating expenses | $142.9M | $109.9M | — |
| Operating income | -$142.9M | $57.6M | — |
| Pretax income | -$131.1M | $53.4M | — |
| Income tax expense | $0 | $1.2M | — |
| Net income | -$131.1M | $52.2M | — |
| Balance Sheet | |||
| Cash and equivalents | $189.2M | $196.8M | — |
| Current assets | $349.7M | $201.7M | — |
| Total assets | $397.1M | $240.5M | — |
| Current liabilities | $22.6M | $20.7M | — |
| Total liabilities | $42.2M | $43.6M | — |
| Stockholders' equity | $355.0M | -$311.2M | -$373.8M |
| Cash Flow Statement | |||
| Cash from operations | -$111.9M | $76.0M | — |
| Depreciation and amortization | $2.4M | $3.3M | — |
| Stock-based compensation | $16.4M | $9.6M | — |
| Capital expenditure | $794,000 | $1.1M | — |
| Free cash flow | -$112.7M | $74.8M | — |
| Dividends paid | $0 | $0 | — |
| Impairments | $0 | $0 | — |
Shares outstanding 55.3M · Free float 77.8%
Annual filing data through FY ended December 31, 2025; float as of July 16, 2026.